Paper39680452
SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts.
Goedeke L and 22 others. J Clin Invest, 2024. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. Papers, record 39680452. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39680452
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sodium-Glucose Transporter 2 Inhibitors | Major topic |
| Heart Failure | Major topic |
| Oxidation-Reduction | Major topic |
| Glucosides | Major topic |
| Benzhydryl Compounds | Major topic |
| Mitochondria, Heart | Major topic |
| Animals | |
| Rats | |
| Male | |
| Rats, Sprague-Dawley | |
| Fatty Acids | |
| Myocardium | |
| Pyruvic Acid | |
| Sodium-Glucose Transporter 2 | |
| Ketones |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 DK007356 | NIDDK NIH HHS | United States | T32DK007356 | PubMed | NIH RePORTER |
| UL1 TR001863 | NCATS NIH HHS | United States | UL1TR001863 | PubMed | NIH RePORTER |
| R01 HL148008 | NHLBI NIH HHS | United States | R01HL148008 | PubMed and NIH | NIH RePORTER |
| U2C DK134901 | NIDDK NIH HHS | United States | U2CDK134901 | PubMed and NIH | NIH RePORTER |
| R01 DK119968 | NIDDK NIH HHS | United States | R01DK119968 | PubMed and NIH | NIH RePORTER |
| P30 DK045735 | NIDDK NIH HHS | United States | P30DK045735 | PubMed and NIH | NIH RePORTER |
| R00 HL150234 | NHLBI NIH HHS | United States | R00HL150234 | PubMed and NIH | NIH RePORTER |
References91
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39041214 | SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice. | Circ Res | 2024 | https://conductscience.org/library/papers/39041214 | PubMed |
| 2 | 31196815 | Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. | Lancet Diabetes Endocrinol | 2019 | https://conductscience.org/library/papers/31196815 | PubMed |
| 3 | 30106622 | Cardiac branched-chain amino acid oxidation is reduced during insulin resistance in the heart. | Am J Physiol Endocrinol Metab | 2018 | https://conductscience.org/library/papers/30106622 | PubMed |
| 4 | 3894678 | Inhibitory effects of the D(-)isomer of 3-hydroxybutyrate on cardiac non-esterified fatty acid uptake and oxygen demand induced by norepinephrine in the intact dog. | J Mol Cell Cardiol | 1985 | https://conductscience.org/library/papers/3894678 | PubMed |
| 5 | 35624663 | Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2/AMPK Pathway. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/35624663 | PubMed |
| 6 | 9462419 | Myocardial infarction with aortic banding. A combined rat model of heart failure. | Jpn Heart J | 1997 | https://conductscience.org/library/papers/9462419 | PubMed |
| 7 | 15314686 | AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. | J Clin Invest | 2004 | https://conductscience.org/library/papers/15314686 | PubMed |
| 8 | 26819376 | The Failing Heart Relies on Ketone Bodies as a Fuel. | Circulation | 2016 | https://conductscience.org/library/papers/26819376 | PubMed |
| 9 | 12147544 | Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. | Circulation | 2002 | https://conductscience.org/library/papers/12147544 | PubMed |
| 10 | 30895697 | A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). | Eur J Heart Fail | 2019 | https://conductscience.org/library/papers/30895697 | PubMed |
| 11 | 23258802 | Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart. | Eur J Heart Fail | 2013 | https://conductscience.org/library/papers/23258802 | PubMed |
| 12 | 30668551 | The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. | JCI Insight | 2019 | https://conductscience.org/library/papers/30668551 | PubMed |
| 13 | 38118414 | Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. | Cell Rep Med | 2023 | https://conductscience.org/library/papers/38118414 | PubMed |
| 14 | 26819374 | Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. | Circulation | 2016 | https://conductscience.org/library/papers/26819374 | PubMed |
| 15 | 36223763 | Extra-cardiac BCAA catabolism lowers blood pressure and protects from heart failure. | Cell Metab | 2022 | https://conductscience.org/library/papers/36223763 | PubMed |
| 16 | 2058715 | Effects of beta-hydroxybutyrate on oxidative metabolism and phosphorylation potential in canine heart in vivo. | Am J Physiol | 1991 | https://conductscience.org/library/papers/2058715 | PubMed |
| 17 | 25311547 | Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure. | Clin Exp Pharmacol Physiol | 2015 | https://conductscience.org/library/papers/25311547 | PubMed |
| 18 | 33983836 | Cardiac Energy Metabolism in Heart Failure. | Circ Res | 2021 | https://conductscience.org/library/papers/33983836 | PubMed |
| 19 | 24657720 | Mitochondrial reactive oxygen species production and elimination. | J Mol Cell Cardiol | 2014 | https://conductscience.org/library/papers/24657720 | PubMed |
| 20 | 23861485 | Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. | Circ Heart Fail | 2013 | https://conductscience.org/library/papers/23861485 | PubMed |
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977703 | Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial (CHOICE-AHF). | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42977703 | PubMed |
| 42814168 | SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42814168 | PubMed |
| 42784236 | Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection. | Pathophysiology | 2026 | https://conductscience.org/library/papers/42784236 | PubMed |
| 42782470 | Roles of inflammation and metabolic dysfunction in cardiovascular diseases: molecular mechanisms and therapeutic targets. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42782470 | PubMed |
| 42694613 | An Integrated Therapeutic Strategy for Cardiorenal Syndrome to Target Oxidative Stress, Inflammation, and Fibrosis. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42694613 | PubMed |
| 42638832 | Metabolic remodeling and cardiac functional adaptation mediated by dapagliflozin in patients with acute heart failure: a retrospective cohort study. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42638832 | PubMed |
| 42591312 | Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42591312 | PubMed |
| 42559753 | Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42559753 | PubMed |
| 42512119 | Apabetalone Drives a Metabolic Shift Towards Ketogenesis and Reduces Liver Steatosis in Diet-Induced Obesity Mice. | Biomedicines | 2026 | https://conductscience.org/library/papers/42512119 | PubMed |
| 42491566 | Decoding cardiorenal crosstalk: Intercellular communication mechanisms and therapeutic insights in cardiorenal syndrome. | iScience | 2026 | https://conductscience.org/library/papers/42491566 | PubMed |
| 42395554 | Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices. | bioRxiv | 2026 | https://conductscience.org/library/papers/42395554 | PubMed |
| 42306580 | Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42306580 | PubMed |
| 42302383 | Metabolic and redox pathway dysregulation in HIV-associated coronary endothelial dysfunction. | Am J Physiol Heart Circ Physiol | 2026 | https://conductscience.org/library/papers/42302383 | PubMed |
| 42199956 | Randomized Controlled Trial of Dapagliflozin for Post-Transplant Diabetes Mellitus in Renal Transplant Recipients. | Kidney Int Rep | 2026 | https://conductscience.org/library/papers/42199956 | PubMed |
| 42146022 | Direct dapagliflozin exposure enhances respiration and membrane hyperpolarization in isolated cardiac mitochondria. | Front Physiol | 2026 | https://conductscience.org/library/papers/42146022 | PubMed |
| 42110178 | Mechanisms and Therapeutic Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42110178 | PubMed |
| 42108503 | Electrostatic lipidopathy drives human diabetic heart failure. | Cardiovasc Diabetol Endocrinol Rep | 2026 | https://conductscience.org/library/papers/42108503 | PubMed |
| 42086691 | Target trial emulation of sodium glucose cotransporter 2 inhibitors and clinical outcomes in diabetes and end stage kidney disease. | Sci Rep | 2026 | https://conductscience.org/library/papers/42086691 | PubMed |
| 42053960 | Dapagliflozin mitigates acute pancreatitis induced by L-arginine in Rats through modulation of TLR-4/NF-κB/NLRP3 pathway: integrated biochemical, histopathological, and in silico study. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/42053960 | PubMed |
| 42038319 | Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42038319 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39680452
GET https://conductscience.org/api/papers/v1/39680452/authors?page=2